Transaction Information
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company") announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the "Existing Warrants") to purchase up to an aggregate of 3,413,286 shares of common stock at $0.7313 per share.
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the warrant exercise transaction.
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier. For more information, please go to www.palisadebio.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.